August J. Troendle, President and CEO of Medpace Holdings, Inc., filed a Form 4 on August 25, 2026, disclosing the sale of common stock on August 21 and August 24, 2026, traded on NASDAQ:MEDP.

Key Highlights

  • First sale: Troendle disposed of 13,995 shares on August 21, 2026, at a weighted average price of $624.45, in multiple transactions ranging from $620.00 to $628.685.
  • Second sale: Troendle disposed of 1,983 shares on August 24, 2026, at a weighted average price of $620.23, in multiple transactions ranging from $620.00 to $621.25.
  • Direct ownership following transactions: Troendle directly holds 545,217 shares of common stock.
  • Indirect ownership: Troendle indirectly holds 4,733,019 shares through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.
  • Transaction basis: According to the filing, the sales were effected pursuant to a limit order placed during an open window period.

Troendle's Share Dispositions and Beneficial Ownership at Medpace Holdings

According to the Form 4 filed with the SEC, August J. Troendle, who serves as President and CEO and is also identified as a Director and 10% Owner of Medpace Holdings, Inc., sold a combined 15,978 shares of common stock across two trading days. The first transaction, on August 21, 2026, involved the disposal of 13,995 shares at a weighted average price of $624.45, with individual sale prices ranging from $620.00 to $628.685. The second transaction, on August 24, 2026, covered 1,983 shares at a weighted average price of $620.23, with prices ranging from $620.00 to $621.25.

The filing states that both transactions were effected pursuant to a limit order placed by the reporting person during an open window period. Following these disposals, Troendle's direct beneficial ownership stands at 545,217 shares of common stock. The filing was signed by Stephen P. Ewald as Attorney-in-Fact for August J. Troendle on August 25, 2026.

In addition to his direct holdings, the filing discloses that Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC. The filing notes that Troendle "is the sole manager and controlling unit holder of Medpace Investors, LLC" and "has sole voting and investment control with respect to the securities held by MPI," though he "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."

What Was Disclosed

The Form 4 reports two open-market sales of Medpace Holdings common stock by President and CEO August J. Troendle on August 21 and August 24, 2026, totaling 15,978 shares, with direct post-transaction ownership of 545,217 shares and indirect ownership of 4,733,019 shares via Medpace Investors, LLC.